 Secondary endpoints include progression-free survival PFS, overall survival OS, objective response rate ORR, duration of response DOR, and toxicity profile of Pembrolizumab. The investigators will also evaluate the expression levels of Programmed death-ligand 1 PD-L-1 in tumor tissue, as well as serum titers of hepatitis B or C in patients with hepatitis B or C, respectively, for whom specimens are available. 